<table cellpadding="2" cellspacing="0" id="t10265122" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4 Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May be Recommended Based on Drug Interaction Studies or Predicted Interaction</caption>
<colgroup>
<col width="30%"></col>
<col width="30%"></col>
<col width="40%"></col>
</colgroup>
<thead>
<tr>
<th>
<content stylecode="bold">
<content stylecode="emphasis">Concomitant Drug Class:<br/>Drug name</content>
</content>
</th>
<th>
<content stylecode="bold">
<content stylecode="emphasis">Effect on Concentration of Tipranavir or Concomitant Drug</content>
</content>
</th>
<th valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Clinical Comment</content>
</content>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">↑ increase, ↓ decrease, ↔ no change, ↕ unable to predict</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td colspan="3">
<br/>HIV-1 Antiviral Agents</td>
</tr>
<tr>
<td>
<content stylecode="bold">
<content stylecode="emphasis">Fusion Inhibitors:</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Enfuvirtide</td>
<td valign="top">↑ Tipranavir</td>
<td>At steady state, tipranavir trough concentrations were approximately 45% higher in patients co-administered enfuvirtide in the Phase 3 trials.  The mechanism for this increase is not known.  Dose adjustments are not recommended.</td>
</tr>
<tr>
<td>
<content stylecode="bold">
<content stylecode="emphasis">Nucleoside Reverse Transcriptase Inhibitors:</content>
</content>
<br/> </td>
<td colspan="2" stylecode="Toprule"> </td>
</tr>
<tr>
<td valign="top">Abacavir</td>
<td valign="top">↓ Abacavir AUC by approximately 40%</td>
<td>Clinical relevance of reduction in abacavir levels not established. Dose adjustment of abacavir cannot be recommended at this time.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Didanosine (EC)</td>
<td valign="top">↓ Didanosine</td>
<td>Clinical relevance of reduction in didanosine levels not established. For optimal absorption, didanosine should be separated from APTIVUS/ritonavir dosing by at least 2 hours.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Zidovudine</td>
<td valign="top">↓ Zidovudine AUC by approximately 35%. ZDV glucuronide concentrations were unaltered.</td>
<td>Clinical relevance of reduction in zidovudine levels not established. Dose adjustment of zidovudine cannot be recommended at this time.</td>
</tr>
<tr>
<td>
<content stylecode="bold">
<content stylecode="emphasis">Protease Inhibitors (co-administered with 200 mg of ritonavir):</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr>
<td valign="top">Fosamprenavir<br/>Lopinavir<br/>Saquinavir</td>
<td valign="top">↓ Amprenavir<br/>↓ Lopinavir<br/>↓ Saquinavir</td>
<td valign="top">Combining a protease inhibitor with APTIVUS/ritonavir is not recommended.</td>
</tr>
<tr>
<td>
<br/>
<content stylecode="bold">
<content stylecode="emphasis">Protease Inhibitors (co-administered with 100 mg of ritonavir):</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Atazanavir</td>
<td valign="top">↓ Atazanavir<br/>↑ Tipranavir</td>
<td> </td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Virus Integrase Strand Transfer Inhibitors:</content>
</content>
<br/> </td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Raltegravir</td>
<td valign="top">↓ Raltegravir</td>
<td valign="top">APTIVUS/ritonavir reduces plasma concentrations of raltegravir.  Since comparable efficacy was observed for this combination in phase 3 studies, dose adjustment is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td>
<br/>Agents for Opportunistic Infections</td>
<td colspan="2"> </td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Antifungals:</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr>
<td valign="top">Fluconazole</td>
<td valign="top">↑ Tipranavir, ↔ Fluconazole</td>
<td valign="top">Fluconazole increases tipranavir concentrations but dose adjustments are not needed. Fluconazole doses &gt;200 mg/day are not recommended.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Itraconazole<br/>Ketoconazole</td>
<td valign="top">↑ Itraconazole (not studied)<br/>↑ Ketoconazole (not studied)</td>
<td valign="top">Based on theoretical considerations itraconazole and ketoconazole should be used with caution. High doses (&gt;200 mg/day) are not recommended.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Voriconazole</td>
<td valign="top">↕ Voriconazole (not studied)</td>
<td valign="top">Due to multiple enzymes involved with voriconazole metabolism, it is difficult to predict the interaction.</td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Antimycobacterials:</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr>
<td valign="top">Clarithromycin</td>
<td valign="top">↑ Tipranavir, ↑ Clarithromycin, <br/>↓ 14-hydroxy-clarithromycin metabolite</td>
<td valign="top">No dose adjustment of APTIVUS or clarithromycin for patients with normal renal function is necessary.<br/> </td>
</tr>
<tr>
<td colspan="2"> </td>
<td>For patients with renal impairment the following dosage adjustments should be considered: <list id="l12035122" listtype="unordered" stylecode="Disc">
<item>For patients with CL<sub>CR</sub> 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%.</item>
<item>For patients with CL<sub>CR</sub> &lt;30 mL/min the dose of clarithromycin should be decreased by 75%. </item>
</list>
</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Rifabutin</td>
<td valign="top">Tipranavir not changed, ↑ Rifabutin <br/>↑ Desacetyl-rifabutin</td>
<td>Single dose study. Dosage reductions of rifabutin by 75% are recommended (e.g., 150 mg every other day). Increased monitoring for adverse events in patients receiving the combination is warranted. Further dosage reduction may be necessary. </td>
</tr>
<tr stylecode="Botrule">
<td valign="bottom"> <br/>Other Agents Commonly Used</td>
<td colspan="2"> </td>
</tr>
<tr>
<td colspan="3">
<content stylecode="bold">
<content stylecode="emphasis">Anticonvulsants:</content>
</content>
<br/> </td>
</tr>
<tr>
<td valign="top">Carbamazepine<br/>Phenobarbital<br/>Phenytoin</td>
<td valign="top">↓ Tipranavir</td>
<td valign="top">Caution should be used when prescribing carbamazepine, phenobarbital and/or phenytoin. APTIVUS may be less effective due to decreased tipranavir plasma concentration in patients taking these agents concomitantly.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Valproic Acid</td>
<td valign="top">↓ Valproic Acid</td>
<td>Caution should be used when prescribing valproic acid. Valproic acid may be less effective due to decreased valproic acid plasma concentration in patients taking APTIVUS concomitantly.</td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Antidepressants:</content>
</content>
<br/>
<br/>Trazodone</td>
<td valign="top">
<br/>
<br/>↑ Trazodone</td>
<td>
<br/>
<br/>Concomitant use of trazodone and APTIVUS/ritonavir may increase plasma concentrations of trazodone. Adverse events of nausea, dizziness, hypotension, and syncope have been observed following co-administration of trazodone and ritonavir. If trazodone is used with a CYP 3A4 inhibitor such as APTIVUS/ritonavir, the combination should be used with caution and a lower dose of trazodone should be considered.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Desipramine</td>
<td valign="top">Combination with APTIVUS/ritonavir not studied<br/>↑ Desipramine</td>
<td valign="top">Dosage reduction and concentration monitoring of desipramine is recommended.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Selective Serotonin-Reuptake Inhibitors:</td>
<td valign="top">Combination with APTIVUS/ritonavir not studied</td>
<td valign="top">Antidepressants have a wide therapeutic index, but doses may need to be adjusted upon initiation of APTIVUS/ritonavir therapy.</td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Fluoxetine<br/>Paroxetine<br/>Sertraline</td>
<td valign="top">↑ Fluoxetine<br/>↑ Paroxetine<br/>↑ Sertraline</td>
<td> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Anti-gout</content>
</content>
<br/>
<br/>Colchicine</td>
<td valign="top">
<br/>
<br/>↑ Colchicine</td>
<td>
<content stylecode="underline">
<content stylecode="emphasis">Patients with renal or hepatic impairment should not be given colchicine with APTIVUS/ritonavir.</content>
</content>
<br/>
<br/>
<content stylecode="underline">
<content stylecode="emphasis">Treatment of gout flares: Co-administration of colchicine in patients on APTIVUS/ritonavir:</content>
</content>
<list id="l12845122" listtype="unordered" stylecode="Disc">
<item>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</item>
</list>
<content stylecode="underline">
<content stylecode="emphasis">Prophylaxis of gout flares:  Co-administration of colchicine in patients on APTIVUS/ritonavir</content>
</content>:<list id="l13062122" listtype="unordered" stylecode="Disc">
<item>If the original colchicine regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.</item>
<item>If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.</item>
</list>
<content stylecode="underline">
<content stylecode="emphasis">Treatment of familial Mediterranean fever (FMF):  Co-administration of colchicine in patients on APTIVUS/ritonavir:</content>
</content>
<list id="l13075122" listtype="unordered" stylecode="Disc">
<item>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Benzodiazepines:</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">Parenterally administered midazolam</td>
<td stylecode="Botrule" valign="top">↑ Midazolam</td>
<td stylecode="Botrule" valign="top">Midazolam is extensively metabolized by CYP 3A4. Increases in the concentration of midazolam are expected to be significantly higher with oral than parenteral administration. Therefore, APTIVUS should not be given with orally administered midazolam [<content stylecode="italics">
<content stylecode="emphasis">see Contraindications <linkhtml href="#Section_4">(4)</linkhtml>
</content>
</content>]. If APTIVUS is co-administered with parenteral midazolam, close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised and dosage adjustments should be considered.</td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Buprenorphine/naloxone</td>
<td valign="top">↔ Buprenorphine<br/>↓ Tipranavir</td>
<td valign="top">APTIVUS/ritonavir did not result in changes in the clinical efficacy of buprenorphine/naloxone.  Compared to historical controls tipranavir C<sub>min</sub> was decreased approximately 40% with this combination.  Dose adjustments cannot be recommended.</td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Calcium Channel Blockers:</content>
</content>
<br/>
<br/>Diltiazem<br/>Felodipine<br/>Nicardipine<br/>Nisoldipine<br/>Verapamil</td>
<td stylecode=" Botrule" valign="top">Combination with APTIVUS/ritonavir not studied. Cannot predict effect of TPV/ritonavir on calcium channel blockers that are dual substrates of CYP3A and P-gp due to conflicting effect of TPV/ritonavir on CYP3A and P-gp.<br/>
<br/>↕ Diltiazem<br/>↑ Felodipine (CYP3A substrate but not P-gp substrate)<br/>↕ Nicardipine<br/>↕ Nisoldipine (CYP3A substrate but not clear whether it is a P-gp substrate)<br/>↕ Verapamil</td>
<td stylecode="Botrule" valign="top">Caution is warranted and clinical monitoring of patients is recommended.</td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Disulfiram/Metronidazole</td>
<td valign="top">Combination with TPV/ritonavir not studied</td>
<td>APTIVUS capsules contain alcohol that can produce disulfiram-like reactions when co-administered with disulfiram or other drugs which produce this reaction (e.g., metronidazole).</td>
</tr>
<tr>
<td stylecode="BOLD" valign="top">
<content stylecode="bold">Endothelin receptor antagonists</content>
</td>
<td> </td>
<td>
<content stylecode="underline">
<content stylecode="emphasis">Co-administration of bosentan in patients on APTIVUS/ritonavir:</content>
</content>
</td>
</tr>
<tr stylecode="Botrule">
<td valign="top">
<br/>Bosentan</td>
<td valign="top">
<br/>↑ Bosentan</td>
<td>
<br/>In patients who have been receiving APTIVUS/ritonavir for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br/>
<br/>
<content stylecode="underline">
<content stylecode="emphasis">Co-administration of APTIVUS/ritonavir in patients on bosentan:</content>
</content>
<br/>
<br/>Discontinue use of bosentan at least 36 hours prior to initiation of APTIVUS/ritonavir.<br/>
<br/>After at least 10 days following the initiation of APTIVUS/ritonavir, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.</td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">HMG-CoA Reductase Inhibitors:</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">Atorvastatin<br/>Rosuvastatin</td>
<td stylecode="Botrule" valign="top">↑ Atorvastatin<br/>↓ Hydroxy-atorvastatin metabolites<br/>↑ Rosuvastatin</td>
<td stylecode="Botrule" valign="top">Avoid co-administration with atorvastatin.</td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Hypoglycemics:</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr>
<td> </td>
<td valign="top">Combination with APTIVUS/ritonavir not studied</td>
<td valign="top">Careful glucose monitoring is warranted.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Glimepiride<br/>Glipizide<br/>Glyburide<br/>Pioglitazone</td>
<td>↔ Glimepiride (CYP 2C9)<br/>↔ Glipizide (CYP 2C9)<br/>↔ Glyburide (CYP 2C9)<br/>↕ Pioglitazone (CYP 2C8 and CYP 3A4)</td>
<td> </td>
</tr>
<tr>
<td valign="top">Repaglinide</td>
<td valign="top">↕ Repaglinide (CYP 2C8 and CYP 3A4)</td>
<td> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Tolbutamide</td>
<td valign="top">↔ Tolbutamide (CYP 2C9)<br/>
<br/>The effect of TPV/ritonavir on CYP 2C8 substrate is not known.</td>
<td> </td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Immunosuppressants:</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr>
<td> </td>
<td valign="top">Combination with APTIVUS/ritonavir not studied. Cannot predict effect of TPV/ritonavir on immunosuppressants due to conflicting effect of TPV/ritonavir on CYP 3A and P-gp.</td>
<td valign="top">Increased frequency of monitoring of plasma levels of immunosuppressant drugs is recommended.</td>
</tr>
<tr>
<td stylecode="Botrule">Cyclosporine<br/>Sirolimus<br/>Tacrolimus</td>
<td stylecode="Botrule">↕ Cyclosporine <br/>↕ Sirolimus<br/>↕ Tacrolimus</td>
<td stylecode="Botrule"> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Inhaled beta agonist:</content>
</content>
<br/>
<br/>Salmeterol</td>
<td valign="top">
<br/>
<br/>↑ Salmeterol</td>
<td stylecode="Botrule">Concurrent administration of APTIVUS/ritonavir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.</td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Inhaled/Nasal Steroids:</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Fluticasone</td>
<td valign="top">↑ Fluticasone</td>
<td valign="top">Concomitant use of fluticasone propionate and APTIVUS/ritonavir may increase plasma concentrations of fluticasone propionate, resulting in significantly reduced serum cortisol concentrations. Co-administration of fluticasone propionate and APTIVUS/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.</td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Narcotic Analgesics:</content>
</content>
<br/> </td>
<td colspan="2" valign="top"> </td>
</tr>
<tr>
<td valign="top">Meperidine </td>
<td valign="top">Combinations with APTIVUS/ritonavir not studied<br/>↓ Meperidine, ↑ Normeperidine</td>
<td valign="top">Dosage increase and long-term use of meperidine are not recommended due to increased concentrations of the metabolite normeperidine which has both analgesic activity and CNS stimulant activity (e.g., seizures).</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Methadone</td>
<td valign="top">↓ Methadone<br/>↓ S-Methadone, ↓ R-Methadone</td>
<td valign="top">Dosage of methadone may need to be increased when co-administered with APTIVUS and 200 mg of ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Oral Contraceptives/Estrogens:</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Ethinyl estradiol</td>
<td valign="top">↓ Ethinyl estradiol concentrations by 50%</td>
<td valign="top">Alternative methods of nonhormonal contraception should be used when estrogen based oral contraceptives are co-administered with APTIVUS and 200 mg of ritonavir. Patients using estrogens as hormone replacement therapy should be clinically monitored for signs of estrogen deficiency. Women using estrogens may have an increased risk of non-serious rash. </td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Proton Pump Inhibitors:</content>
</content>
<br/> </td>
<td colspan="2" valign="top"> </td>
</tr>
<tr stylecode="Botrule">
<td valign="top">Omeprazole</td>
<td valign="top">↓ Omeprazole, ↔ Tipranavir</td>
<td valign="top">Dosage of omeprazole may need to be increased when co-administered with APTIVUS and ritonavir.</td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">PDE-5 Inhibitors:</content>
</content>
</td>
<td colspan="2"> </td>
</tr>
<tr>
<td> </td>
<td valign="top">Only the combination of tadalafil with APTIVUS/ritonavir has been studied (at doses used for treatment of erectile dysfunction).<br/> </td>
<td valign="top">Co-administration with APTIVUS/ritonavir may result in an increase in PDE-5 inhibitor-associated adverse events, including hypotension, syncope, visual disturbances, and priapism.</td>
</tr>
<tr valign="top">
<td valign="top">Sildenafil</td>
<td valign="top">↑ Sildenafil (not studied)</td>
<td>
<content stylecode="underline">
<content stylecode="emphasis">Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH):</content>
</content>
<br/>
<br/>
<list id="l15623122" listtype="unordered" stylecode="Disc">
<item>Use of sildenafil (Revatio) is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) [<content stylecode="italics">see Contraindications (<linkhtml href="#Section_4.2">4.2</linkhtml>)</content>].<br/>
<br/>
</item>
<item>The following dose adjustments are recommended for use of tadalafil (Adcirca) with APTIVUS/ritonavir:</item>
</list>
</td>
</tr>
<tr>
<td valign="top">Tadalafil</td>
<td valign="top">↑ Tadalafil with first dose APTIVUS/ritonavir<br/>↔ Tadalafil at APTIVUS/ritonavir steady-state</td>
<td>
<content stylecode="underline">
<content stylecode="emphasis">Co-administration of tadalafil (Adcirca) in patients on APTIVUS/ritonavir:</content>
</content>
<br/>
<br/>In patients receiving APTIVUS/ritonavir for at least one week, start Adcirca at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.</td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">Vardenafil</td>
<td stylecode="Botrule" valign="top">↑ Vardenafil (not studied)</td>
<td stylecode="Botrule" valign="top">
<content stylecode="underline">
<content stylecode="emphasis">Co-administration of APTIVUS/ritonavir in patients on tadalafil (Adcirca):</content>
</content>
<br/>
<br/> Avoid use of tadalafil (Adcirca) during the initiation of APTIVUS/ritonavir. Stop Adcirca at least 24 hours prior to starting APTIVUS/ritonavir. After at least one week following the initiation of APTIVUS/ritonavir, resume Adcirca at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br/>
<br/>
<content stylecode="underline">
<content stylecode="emphasis">Use of PDE-5 inhibitors for erectile dysfunction:</content>
</content>
<br/>
<br/>Concomitant use of PDE-5 inhibitors with APTIVUS/ritonavir should be used with caution and in no case should the starting dose of:<list id="l15895122" listtype="unordered" stylecode="Disc">
<item>sildenafil exceed 25 mg within 48 hours </item>
<item>tadalafil exceed 10 mg every 72 hours</item>
<item>vardenafil exceed 2.5 mg every 72 hours</item>
</list>Use with increased monitoring for adverse events.</td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">Warfarin</td>
<td stylecode="Botrule" valign="top">↔ S-Warfarin</td>
<td stylecode="Botrule" valign="top">Frequent INR (international normalized ratio) monitoring upon initiation of APTIVUS/ritonavir therapy.</td>
</tr>
</tbody>
</table>